We are live on !
Find out more
ACPLP
ACT Capital Partners, L.P. Portfolio holdings
AUM
$154M
This Fund
S&P 500
This Quarter Est. Return
-1.02%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$154M
AUM Growth
–
Cap. Flow
+$157M
Cap. Flow % of AUM
Cap. Flow %
101.65%
Top 10 Holdings %
Top 10 Hldgs %
64.62%
Holding
58
New
58
Increased
–
Reduced
–
Closed
–
Avg Time Held
Equity + Options
0
years
Top 10 Avg Time Held
Equity + Options
0
years
Top 20 Avg Time Held
Equity + Options
0
years
Avg Time Held Equity only
0
years
Top 10 Avg Time Held Equity only
0
years
Top 20 Avg Time Held Equity only
0
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Chevron
CVX
|
+$14.8M |
| 2 |
Krystal Biotech
KRYS
|
+$14.5M |
| 3 |
TG Therapeutics
TGTX
|
+$12.8M |
| 4 |
ExxonMobil
XOM
|
+$12.3M |
| 5 |
Amazon
AMZN
|
+$10.8M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 49.89% |
| 2 | Energy | 21.53% |
| 3 | Technology | 12.48% |
| 4 | Consumer Discretionary | 10.29% |
| 5 | Miscellaneous | 2.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Chevron
CVX
$415B
| $15.3M | 9.95% |
+75,000
| New | +$14.8M |
2026 Q3
0 quarters
|
|
|
2
Krystal Biotech
KRYS
$8.92B
| $14M | 9.07% |
+42,000
| New | +$14.5M |
2026 Q3
0 quarters
|
|
|
3
TG Therapeutics
TGTX
$9.16B
| $13.2M | 8.59% |
+237,200
| New | +$12.8M |
2026 Q3
0 quarters
|
|
|
4
ExxonMobil
XOM
$677B
| $12.8M | 8.3% |
+78,500
| New | +$12.3M |
2026 Q3
0 quarters
|
|
|
5
Amazon
AMZN
$2.8T
| $10.6M | 6.88% |
+42,500
| New | +$10.8M |
2026 Q3
0 quarters
|
|
6
Abivax
ABVX
$7.5B
| $8.42M | 5.47% |
+85,000
| New | +$10.2M |
2026 Q3
0 quarters
|
|
7
Viking Therapeutics
VKTX
$3.42B
| $7.18M | 4.66% |
+220,200
| New | +$7.63M |
2026 Q3
0 quarters
|
|
8
SK Hynix Inc
SKHY
$898B
| $6.39M | 4.15% |
+34,700
| New | +$5.74M |
2026 Q3
0 quarters
|
|
9
Arrowhead Research
ARWR
$8.22B
| $6.15M | 4% |
+94,000
| New | +$7.61M |
2026 Q3
0 quarters
|
|
10
Nektar Therapeutics
NKTR
$1.27B
| $5.47M | 3.56% |
+90,400
| New | +$6.35M |
2026 Q3
0 quarters
|
|
11
Tesla
TSLA
$1.42T
| $5.25M | 3.41% |
+14,800
| New | +$5.3M |
2026 Q3
0 quarters
|
|
12
Celcuity
CELC
$3.27B
| $4.66M | 3.03% |
+58,650
| New | +$5.34M |
2026 Q3
0 quarters
|
|
13
Micron Technology
MU
$781B
| $3.73M | 2.42% |
+3,500
| New | +$3.32M |
2026 Q3
0 quarters
|
|
14
Nuvation Bio
NUVB
$1.46B
| $3.25M | 2.11% |
+579,500
| New | +$3.64M |
2026 Q3
0 quarters
|
|
15
Palvella Therapeutics
PVLA
$2.53B
| $3.1M | 2.02% |
+22,500
| New | +$3.34M |
2026 Q3
0 quarters
|
|
16
Energy Transfer Partners
ET
$65.1B
| $2.63M | 1.71% |
+133,100
| New | +$2.75M |
2026 Q3
0 quarters
|
|
17
Bloom Energy
BE
$51.2B
| $2.49M | 1.62% |
+9,000
| New | +$2.13M |
2026 Q3
0 quarters
|
|
18
AST SpaceMobile
ASTS
$9.7B
| $2.3M | 1.49% |
+39,000
| New | +$2.51M |
2026 Q3
0 quarters
|
|
19
Freeport-McMoran
FCX
$85.3B
| $2.28M | 1.48% |
+32,500
| New | +$2.21M |
2026 Q3
0 quarters
|
|
20
Cameco
CCJ
$31.1B
| $2.2M | 1.43% |
+25,400
| New | +$2.39M |
2026 Q3
0 quarters
|
|
21
Mineralys Therapeutics
MLYS
$1.36B
| $2.2M | 1.43% |
+87,400
| New | +$2.38M |
2026 Q3
0 quarters
|
|
22
AXT Inc
AXTI
$2.55B
| $1.95M | 1.27% |
+25,200
| New | +$1.63M |
2026 Q3
0 quarters
|
|
|
HELP
23
Helus Pharma Inc. Common Stock
HELP
$655M
| $1.66M | 1.08% |
+135,000
| New | +$1.41M |
2026 Q3
0 quarters
|
|
24
Candel Therapeutics
CADL
$670M
| $1.57M | 1.02% |
+150,500
| New | +$1.67M |
2026 Q3
0 quarters
|
|
|
25
CALL
SK Hynix Inc
SKHY
$898B
| $1.29M | 0.84% |
+7,000
| New | +$1.16M |
2026 Q3
0 quarters
|
|
Similar funds
MWM
GFG
OP
ACT Capital Partners, L.P.'s Q3 2026 Portfolio in Review
Q3 2026 is the first quarter with a 13F filing on record for ACT Capital Partners, L.P., which disclosed 58 positions worth $154M. Its ten largest holdings account for 65% of the portfolio.
Its largest position is Chevron: 75,000 shares worth $15.3M.
By sector, the portfolio is most concentrated in Healthcare at 50% of assets, followed by Energy and Technology.
- ACT Capital Partners, L.P.'s largest Q3 2026 buy was Chevron: 75,000 shares worth $15.3M.
- ACT Capital Partners, L.P.'s ten largest holdings make up 65% of its $154M portfolio in Q3 2026.
- ACT Capital Partners, L.P. disclosed 58 positions in Q3 2026, its first 13F filing on record.
Based on ACT Capital Partners, L.P.'s 13F filing for Q3 2026, filed 6 Nov 2026.